nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—CYP3A4—type 2 diabetes mellitus	0.137	1	CbGaD
Sirolimus—SLCO1B1—Repaglinide—type 2 diabetes mellitus	0.0548	0.109	CbGbCtD
Sirolimus—SLC47A1—Metformin—type 2 diabetes mellitus	0.0534	0.106	CbGbCtD
Sirolimus—SLCO1B1—Pioglitazone—type 2 diabetes mellitus	0.0495	0.0983	CbGbCtD
Sirolimus—SLCO1B1—Rosiglitazone—type 2 diabetes mellitus	0.0457	0.0907	CbGbCtD
Sirolimus—SLCO1B1—Valsartan—type 2 diabetes mellitus	0.0404	0.0802	CbGbCtD
Sirolimus—SLCO1B1—Losartan—type 2 diabetes mellitus	0.0232	0.046	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Nateglinide—type 2 diabetes mellitus	0.022	0.0437	CbGbCtD
Sirolimus—CYP3A7—Nateglinide—type 2 diabetes mellitus	0.022	0.0437	CbGbCtD
Sirolimus—ABCB1—Linagliptin—type 2 diabetes mellitus	0.022	0.0437	CbGbCtD
Sirolimus—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0196	0.039	CbGbCtD
Sirolimus—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.0165	0.0328	CbGbCtD
Sirolimus—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0142	0.0282	CbGbCtD
Sirolimus—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0132	0.0262	CbGbCtD
Sirolimus—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0118	0.0233	CbGbCtD
Sirolimus—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0108	0.0213	CbGbCtD
Sirolimus—CYP3A5—Losartan—type 2 diabetes mellitus	0.0102	0.0203	CbGbCtD
Sirolimus—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00975	0.0194	CbGbCtD
Sirolimus—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0094	0.0187	CbGbCtD
Sirolimus—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0085	0.0169	CbGbCtD
Sirolimus—ABCB1—Glyburide—type 2 diabetes mellitus	0.00726	0.0144	CbGbCtD
Sirolimus—ABCB1—Losartan—type 2 diabetes mellitus	0.00664	0.0132	CbGbCtD
Sirolimus—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00644	0.0128	CbGbCtD
Sirolimus—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00618	0.0123	CbGbCtD
Sirolimus—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00618	0.0123	CbGbCtD
Sirolimus—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00584	0.0116	CbGbCtD
Sirolimus—MTOR—leg—type 2 diabetes mellitus	0.00492	0.111	CbGeAlD
Sirolimus—MTOR—hindlimb—type 2 diabetes mellitus	0.00439	0.0992	CbGeAlD
Sirolimus—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00435	0.00864	CbGbCtD
Sirolimus—CYP3A4—Losartan—type 2 diabetes mellitus	0.00398	0.0079	CbGbCtD
Sirolimus—EIF4E—cardiovascular system—type 2 diabetes mellitus	0.00242	0.0546	CbGeAlD
Sirolimus—EIF4E—kidney—type 2 diabetes mellitus	0.00237	0.0534	CbGeAlD
Sirolimus—EIF4E—pancreas—type 2 diabetes mellitus	0.00235	0.0531	CbGeAlD
Sirolimus—FGF2—islet of Langerhans—type 2 diabetes mellitus	0.00204	0.0461	CbGeAlD
Sirolimus—EIF4E—liver—type 2 diabetes mellitus	0.0015	0.0338	CbGeAlD
Sirolimus—FGF2—adipose tissue—type 2 diabetes mellitus	0.0013	0.0294	CbGeAlD
Sirolimus—MTOR—retina—type 2 diabetes mellitus	0.00111	0.025	CbGeAlD
Sirolimus—FKBP1A—retina—type 2 diabetes mellitus	0.000995	0.0225	CbGeAlD
Sirolimus—CYP3A7-CYP3A51P—nephron tubule—type 2 diabetes mellitus	0.000986	0.0223	CbGeAlD
Sirolimus—MTOR—cardiovascular system—type 2 diabetes mellitus	0.000936	0.0211	CbGeAlD
Sirolimus—MTOR—kidney—type 2 diabetes mellitus	0.000915	0.0207	CbGeAlD
Sirolimus—MTOR—pancreas—type 2 diabetes mellitus	0.000909	0.0205	CbGeAlD
Sirolimus—CYP3A7-CYP3A51P—cortex of kidney—type 2 diabetes mellitus	0.000844	0.0191	CbGeAlD
Sirolimus—FKBP1A—cardiovascular system—type 2 diabetes mellitus	0.000841	0.019	CbGeAlD
Sirolimus—MTOR—adipose tissue—type 2 diabetes mellitus	0.000825	0.0186	CbGeAlD
Sirolimus—FKBP1A—kidney—type 2 diabetes mellitus	0.000823	0.0186	CbGeAlD
Sirolimus—FKBP1A—pancreas—type 2 diabetes mellitus	0.000818	0.0185	CbGeAlD
Sirolimus—SLC47A1—nephron tubule—type 2 diabetes mellitus	0.000805	0.0182	CbGeAlD
Sirolimus—FKBP1A—cortex of kidney—type 2 diabetes mellitus	0.000802	0.0181	CbGeAlD
Sirolimus—FKBP1A—adipose tissue—type 2 diabetes mellitus	0.000742	0.0168	CbGeAlD
Sirolimus—SLC47A1—kidney—type 2 diabetes mellitus	0.000708	0.016	CbGeAlD
Sirolimus—SLCO1B1—kidney—type 2 diabetes mellitus	0.000699	0.0158	CbGeAlD
Sirolimus—SLC47A1—cortex of kidney—type 2 diabetes mellitus	0.000689	0.0156	CbGeAlD
Sirolimus—CYP3A7—liver—type 2 diabetes mellitus	0.000644	0.0145	CbGeAlD
Sirolimus—SLC47A1—adipose tissue—type 2 diabetes mellitus	0.000638	0.0144	CbGeAlD
Sirolimus—MTOR—liver—type 2 diabetes mellitus	0.000579	0.0131	CbGeAlD
Sirolimus—Pimecrolimus—CYP3A4—type 2 diabetes mellitus	0.000562	0.264	CrCbGaD
Sirolimus—Everolimus—CYP3A4—type 2 diabetes mellitus	0.000562	0.264	CrCbGaD
Sirolimus—CYP3A7-CYP3A51P—liver—type 2 diabetes mellitus	0.000547	0.0124	CbGeAlD
Sirolimus—FKBP1A—liver—type 2 diabetes mellitus	0.00052	0.0118	CbGeAlD
Sirolimus—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000507	0.0114	CbGeAlD
Sirolimus—SLC47A1—liver—type 2 diabetes mellitus	0.000447	0.0101	CbGeAlD
Sirolimus—SLCO1B1—liver—type 2 diabetes mellitus	0.000442	0.00997	CbGeAlD
Sirolimus—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000408	0.00921	CbGeAlD
Sirolimus—Temsirolimus—CYP3A4—type 2 diabetes mellitus	0.000379	0.178	CrCbGaD
Sirolimus—CYP3A5—kidney—type 2 diabetes mellitus	0.000359	0.0081	CbGeAlD
Sirolimus—CYP3A5—pancreas—type 2 diabetes mellitus	0.000356	0.00804	CbGeAlD
Sirolimus—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.000349	0.00789	CbGeAlD
Sirolimus—Tacrolimus—CYP3A4—type 2 diabetes mellitus	0.000334	0.157	CrCbGaD
Sirolimus—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000323	0.0073	CbGeAlD
Sirolimus—Tacrolimus—ALB—type 2 diabetes mellitus	0.000291	0.137	CrCbGaD
Sirolimus—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000269	0.00608	CbGeAlD
Sirolimus—CYP3A4—kidney—type 2 diabetes mellitus	0.000269	0.00608	CbGeAlD
Sirolimus—ABCB1—retina—type 2 diabetes mellitus	0.00023	0.0052	CbGeAlD
Sirolimus—CYP3A5—liver—type 2 diabetes mellitus	0.000227	0.00512	CbGeAlD
Sirolimus—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000217	0.00489	CbGeAlD
Sirolimus—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000195	0.0044	CbGeAlD
Sirolimus—ABCB1—kidney—type 2 diabetes mellitus	0.00019	0.0043	CbGeAlD
Sirolimus—ABCB1—pancreas—type 2 diabetes mellitus	0.000189	0.00427	CbGeAlD
Sirolimus—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000185	0.00419	CbGeAlD
Sirolimus—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000172	0.00388	CbGeAlD
Sirolimus—CYP3A4—liver—type 2 diabetes mellitus	0.00017	0.00384	CbGeAlD
Sirolimus—ABCB1—liver—type 2 diabetes mellitus	0.00012	0.00272	CbGeAlD
Sirolimus—Headache—Sitagliptin—type 2 diabetes mellitus	6.95e-05	0.000376	CcSEcCtD
Sirolimus—Anaemia—Losartan—type 2 diabetes mellitus	6.93e-05	0.000375	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	6.9e-05	0.000373	CcSEcCtD
Sirolimus—Agitation—Losartan—type 2 diabetes mellitus	6.89e-05	0.000373	CcSEcCtD
Sirolimus—Oedema—Metformin—type 2 diabetes mellitus	6.89e-05	0.000373	CcSEcCtD
Sirolimus—Tinnitus—Ramipril—type 2 diabetes mellitus	6.89e-05	0.000373	CcSEcCtD
Sirolimus—Hypertension—Irbesartan—type 2 diabetes mellitus	6.88e-05	0.000373	CcSEcCtD
Sirolimus—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	6.87e-05	0.000372	CcSEcCtD
Sirolimus—Angioedema—Losartan—type 2 diabetes mellitus	6.85e-05	0.000371	CcSEcCtD
Sirolimus—Infection—Metformin—type 2 diabetes mellitus	6.85e-05	0.000371	CcSEcCtD
Sirolimus—Insomnia—Valsartan—type 2 diabetes mellitus	6.85e-05	0.000371	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	6.81e-05	0.000369	CcSEcCtD
Sirolimus—Paraesthesia—Valsartan—type 2 diabetes mellitus	6.8e-05	0.000368	CcSEcCtD
Sirolimus—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	6.79e-05	0.000368	CcSEcCtD
Sirolimus—Arthralgia—Irbesartan—type 2 diabetes mellitus	6.79e-05	0.000367	CcSEcCtD
Sirolimus—Myalgia—Irbesartan—type 2 diabetes mellitus	6.79e-05	0.000367	CcSEcCtD
Sirolimus—Chest pain—Irbesartan—type 2 diabetes mellitus	6.79e-05	0.000367	CcSEcCtD
Sirolimus—Shock—Metformin—type 2 diabetes mellitus	6.78e-05	0.000367	CcSEcCtD
Sirolimus—Insomnia—Orlistat—type 2 diabetes mellitus	6.76e-05	0.000366	CcSEcCtD
Sirolimus—Malaise—Losartan—type 2 diabetes mellitus	6.76e-05	0.000366	CcSEcCtD
Sirolimus—Anxiety—Irbesartan—type 2 diabetes mellitus	6.76e-05	0.000366	CcSEcCtD
Sirolimus—Hypersensitivity—Glyburide—type 2 diabetes mellitus	6.76e-05	0.000366	CcSEcCtD
Sirolimus—Nervous system disorder—Metformin—type 2 diabetes mellitus	6.76e-05	0.000366	CcSEcCtD
Sirolimus—Thrombocytopenia—Metformin—type 2 diabetes mellitus	6.75e-05	0.000365	CcSEcCtD
Sirolimus—Dyspnoea—Valsartan—type 2 diabetes mellitus	6.75e-05	0.000365	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	6.74e-05	0.000365	CcSEcCtD
Sirolimus—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	6.74e-05	0.000365	CcSEcCtD
Sirolimus—Somnolence—Valsartan—type 2 diabetes mellitus	6.73e-05	0.000364	CcSEcCtD
Sirolimus—Syncope—Losartan—type 2 diabetes mellitus	6.73e-05	0.000364	CcSEcCtD
Sirolimus—Paraesthesia—Orlistat—type 2 diabetes mellitus	6.72e-05	0.000364	CcSEcCtD
Sirolimus—Leukopenia—Losartan—type 2 diabetes mellitus	6.71e-05	0.000364	CcSEcCtD
Sirolimus—Discomfort—Irbesartan—type 2 diabetes mellitus	6.7e-05	0.000363	CcSEcCtD
Sirolimus—Skin disorder—Metformin—type 2 diabetes mellitus	6.69e-05	0.000363	CcSEcCtD
Sirolimus—Immune system disorder—Ramipril—type 2 diabetes mellitus	6.67e-05	0.000361	CcSEcCtD
Sirolimus—Hyperhidrosis—Metformin—type 2 diabetes mellitus	6.66e-05	0.000361	CcSEcCtD
Sirolimus—Dyspepsia—Valsartan—type 2 diabetes mellitus	6.66e-05	0.000361	CcSEcCtD
Sirolimus—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	6.66e-05	0.000361	CcSEcCtD
Sirolimus—Dizziness—Bromocriptine—type 2 diabetes mellitus	6.64e-05	0.000359	CcSEcCtD
Sirolimus—Palpitations—Losartan—type 2 diabetes mellitus	6.63e-05	0.000359	CcSEcCtD
Sirolimus—Nausea—Glimepiride—type 2 diabetes mellitus	6.61e-05	0.000358	CcSEcCtD
Sirolimus—Loss of consciousness—Losartan—type 2 diabetes mellitus	6.59e-05	0.000357	CcSEcCtD
Sirolimus—Nausea—Sitagliptin—type 2 diabetes mellitus	6.59e-05	0.000357	CcSEcCtD
Sirolimus—Dyspepsia—Orlistat—type 2 diabetes mellitus	6.58e-05	0.000357	CcSEcCtD
Sirolimus—Asthenia—Glyburide—type 2 diabetes mellitus	6.58e-05	0.000357	CcSEcCtD
Sirolimus—Decreased appetite—Valsartan—type 2 diabetes mellitus	6.58e-05	0.000356	CcSEcCtD
Sirolimus—Anorexia—Metformin—type 2 diabetes mellitus	6.57e-05	0.000356	CcSEcCtD
Sirolimus—Cough—Losartan—type 2 diabetes mellitus	6.55e-05	0.000354	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	6.53e-05	0.000354	CcSEcCtD
Sirolimus—Abdominal pain—Gliclazide—type 2 diabetes mellitus	6.51e-05	0.000353	CcSEcCtD
Sirolimus—Body temperature increased—Gliclazide—type 2 diabetes mellitus	6.51e-05	0.000353	CcSEcCtD
Sirolimus—Oedema—Irbesartan—type 2 diabetes mellitus	6.5e-05	0.000352	CcSEcCtD
Sirolimus—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	6.5e-05	0.000352	CcSEcCtD
Sirolimus—Decreased appetite—Orlistat—type 2 diabetes mellitus	6.5e-05	0.000352	CcSEcCtD
Sirolimus—Pruritus—Glyburide—type 2 diabetes mellitus	6.49e-05	0.000352	CcSEcCtD
Sirolimus—Constipation—Valsartan—type 2 diabetes mellitus	6.47e-05	0.000351	CcSEcCtD
Sirolimus—Infection—Irbesartan—type 2 diabetes mellitus	6.46e-05	0.00035	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	6.46e-05	0.00035	CcSEcCtD
Sirolimus—Hypotension—Metformin—type 2 diabetes mellitus	6.44e-05	0.000349	CcSEcCtD
Sirolimus—Malnutrition—Ramipril—type 2 diabetes mellitus	6.43e-05	0.000348	CcSEcCtD
Sirolimus—Shock—Irbesartan—type 2 diabetes mellitus	6.4e-05	0.000347	CcSEcCtD
Sirolimus—Pain—Orlistat—type 2 diabetes mellitus	6.4e-05	0.000346	CcSEcCtD
Sirolimus—Arthralgia—Losartan—type 2 diabetes mellitus	6.39e-05	0.000346	CcSEcCtD
Sirolimus—Myalgia—Losartan—type 2 diabetes mellitus	6.39e-05	0.000346	CcSEcCtD
Sirolimus—Chest pain—Losartan—type 2 diabetes mellitus	6.39e-05	0.000346	CcSEcCtD
Sirolimus—Vomiting—Bromocriptine—type 2 diabetes mellitus	6.38e-05	0.000346	CcSEcCtD
Sirolimus—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	6.38e-05	0.000345	CcSEcCtD
Sirolimus—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	6.37e-05	0.000345	CcSEcCtD
Sirolimus—Anxiety—Losartan—type 2 diabetes mellitus	6.36e-05	0.000345	CcSEcCtD
Sirolimus—Tachycardia—Irbesartan—type 2 diabetes mellitus	6.35e-05	0.000344	CcSEcCtD
Sirolimus—Rash—Bromocriptine—type 2 diabetes mellitus	6.33e-05	0.000343	CcSEcCtD
Sirolimus—Dermatitis—Bromocriptine—type 2 diabetes mellitus	6.32e-05	0.000342	CcSEcCtD
Sirolimus—Skin disorder—Irbesartan—type 2 diabetes mellitus	6.32e-05	0.000342	CcSEcCtD
Sirolimus—Tension—Ramipril—type 2 diabetes mellitus	6.31e-05	0.000342	CcSEcCtD
Sirolimus—Discomfort—Losartan—type 2 diabetes mellitus	6.31e-05	0.000342	CcSEcCtD
Sirolimus—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	6.29e-05	0.000341	CcSEcCtD
Sirolimus—Headache—Bromocriptine—type 2 diabetes mellitus	6.29e-05	0.000341	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	6.28e-05	0.00034	CcSEcCtD
Sirolimus—Diarrhoea—Glyburide—type 2 diabetes mellitus	6.28e-05	0.00034	CcSEcCtD
Sirolimus—Nervousness—Ramipril—type 2 diabetes mellitus	6.25e-05	0.000338	CcSEcCtD
Sirolimus—Anorexia—Irbesartan—type 2 diabetes mellitus	6.2e-05	0.000336	CcSEcCtD
Sirolimus—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	6.19e-05	0.000335	CcSEcCtD
Sirolimus—Paraesthesia—Metformin—type 2 diabetes mellitus	6.19e-05	0.000335	CcSEcCtD
Sirolimus—Muscle spasms—Ramipril—type 2 diabetes mellitus	6.18e-05	0.000335	CcSEcCtD
Sirolimus—Confusional state—Losartan—type 2 diabetes mellitus	6.17e-05	0.000334	CcSEcCtD
Sirolimus—Feeling abnormal—Orlistat—type 2 diabetes mellitus	6.16e-05	0.000334	CcSEcCtD
Sirolimus—Dyspnoea—Metformin—type 2 diabetes mellitus	6.14e-05	0.000333	CcSEcCtD
Sirolimus—Somnolence—Metformin—type 2 diabetes mellitus	6.13e-05	0.000332	CcSEcCtD
Sirolimus—Oedema—Losartan—type 2 diabetes mellitus	6.12e-05	0.000332	CcSEcCtD
Sirolimus—Anaphylactic shock—Losartan—type 2 diabetes mellitus	6.12e-05	0.000332	CcSEcCtD
Sirolimus—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	6.12e-05	0.000331	CcSEcCtD
Sirolimus—Infection—Losartan—type 2 diabetes mellitus	6.08e-05	0.000329	CcSEcCtD
Sirolimus—Hypotension—Irbesartan—type 2 diabetes mellitus	6.08e-05	0.000329	CcSEcCtD
Sirolimus—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	6.07e-05	0.000329	CcSEcCtD
Sirolimus—Dyspepsia—Metformin—type 2 diabetes mellitus	6.07e-05	0.000329	CcSEcCtD
Sirolimus—Tremor—Ramipril—type 2 diabetes mellitus	6.03e-05	0.000326	CcSEcCtD
Sirolimus—Shock—Losartan—type 2 diabetes mellitus	6.02e-05	0.000326	CcSEcCtD
Sirolimus—Nervous system disorder—Losartan—type 2 diabetes mellitus	6e-05	0.000325	CcSEcCtD
Sirolimus—Thrombocytopenia—Losartan—type 2 diabetes mellitus	5.99e-05	0.000325	CcSEcCtD
Sirolimus—Decreased appetite—Metformin—type 2 diabetes mellitus	5.99e-05	0.000325	CcSEcCtD
Sirolimus—Abdominal pain—Valsartan—type 2 diabetes mellitus	5.98e-05	0.000324	CcSEcCtD
Sirolimus—Tachycardia—Losartan—type 2 diabetes mellitus	5.97e-05	0.000324	CcSEcCtD
Sirolimus—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	5.97e-05	0.000323	CcSEcCtD
Sirolimus—Nausea—Bromocriptine—type 2 diabetes mellitus	5.96e-05	0.000323	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	5.95e-05	0.000322	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	5.93e-05	0.000321	CcSEcCtD
Sirolimus—Hyperhidrosis—Losartan—type 2 diabetes mellitus	5.92e-05	0.00032	CcSEcCtD
Sirolimus—Abdominal pain—Orlistat—type 2 diabetes mellitus	5.91e-05	0.00032	CcSEcCtD
Sirolimus—Body temperature increased—Orlistat—type 2 diabetes mellitus	5.91e-05	0.00032	CcSEcCtD
Sirolimus—Asthenia—Gliclazide—type 2 diabetes mellitus	5.91e-05	0.00032	CcSEcCtD
Sirolimus—Agitation—Ramipril—type 2 diabetes mellitus	5.91e-05	0.00032	CcSEcCtD
Sirolimus—Constipation—Metformin—type 2 diabetes mellitus	5.89e-05	0.000319	CcSEcCtD
Sirolimus—Angioedema—Ramipril—type 2 diabetes mellitus	5.88e-05	0.000318	CcSEcCtD
Sirolimus—Paraesthesia—Irbesartan—type 2 diabetes mellitus	5.84e-05	0.000316	CcSEcCtD
Sirolimus—Anorexia—Losartan—type 2 diabetes mellitus	5.84e-05	0.000316	CcSEcCtD
Sirolimus—Vomiting—Glyburide—type 2 diabetes mellitus	5.83e-05	0.000316	CcSEcCtD
Sirolimus—Pruritus—Gliclazide—type 2 diabetes mellitus	5.83e-05	0.000316	CcSEcCtD
Sirolimus—Malaise—Ramipril—type 2 diabetes mellitus	5.8e-05	0.000314	CcSEcCtD
Sirolimus—Dyspnoea—Irbesartan—type 2 diabetes mellitus	5.8e-05	0.000314	CcSEcCtD
Sirolimus—Rash—Glyburide—type 2 diabetes mellitus	5.78e-05	0.000313	CcSEcCtD
Sirolimus—Somnolence—Irbesartan—type 2 diabetes mellitus	5.78e-05	0.000313	CcSEcCtD
Sirolimus—Dermatitis—Glyburide—type 2 diabetes mellitus	5.78e-05	0.000313	CcSEcCtD
Sirolimus—Syncope—Ramipril—type 2 diabetes mellitus	5.77e-05	0.000312	CcSEcCtD
Sirolimus—Leukopenia—Ramipril—type 2 diabetes mellitus	5.76e-05	0.000312	CcSEcCtD
Sirolimus—Headache—Glyburide—type 2 diabetes mellitus	5.75e-05	0.000311	CcSEcCtD
Sirolimus—Dyspepsia—Irbesartan—type 2 diabetes mellitus	5.73e-05	0.00031	CcSEcCtD
Sirolimus—Hypotension—Losartan—type 2 diabetes mellitus	5.72e-05	0.00031	CcSEcCtD
Sirolimus—Palpitations—Ramipril—type 2 diabetes mellitus	5.68e-05	0.000308	CcSEcCtD
Sirolimus—Feeling abnormal—Metformin—type 2 diabetes mellitus	5.68e-05	0.000308	CcSEcCtD
Sirolimus—Decreased appetite—Irbesartan—type 2 diabetes mellitus	5.65e-05	0.000306	CcSEcCtD
Sirolimus—Loss of consciousness—Ramipril—type 2 diabetes mellitus	5.65e-05	0.000306	CcSEcCtD
Sirolimus—Diarrhoea—Gliclazide—type 2 diabetes mellitus	5.64e-05	0.000305	CcSEcCtD
Sirolimus—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	5.64e-05	0.000305	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	5.62e-05	0.000304	CcSEcCtD
Sirolimus—Cough—Ramipril—type 2 diabetes mellitus	5.61e-05	0.000304	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	5.58e-05	0.000302	CcSEcCtD
Sirolimus—Hypersensitivity—Valsartan—type 2 diabetes mellitus	5.58e-05	0.000302	CcSEcCtD
Sirolimus—Pain—Irbesartan—type 2 diabetes mellitus	5.56e-05	0.000301	CcSEcCtD
Sirolimus—Constipation—Irbesartan—type 2 diabetes mellitus	5.56e-05	0.000301	CcSEcCtD
Sirolimus—Insomnia—Losartan—type 2 diabetes mellitus	5.54e-05	0.0003	CcSEcCtD
Sirolimus—Hypersensitivity—Orlistat—type 2 diabetes mellitus	5.51e-05	0.000298	CcSEcCtD
Sirolimus—Paraesthesia—Losartan—type 2 diabetes mellitus	5.5e-05	0.000298	CcSEcCtD
Sirolimus—Myalgia—Ramipril—type 2 diabetes mellitus	5.48e-05	0.000297	CcSEcCtD
Sirolimus—Chest pain—Ramipril—type 2 diabetes mellitus	5.48e-05	0.000297	CcSEcCtD
Sirolimus—Arthralgia—Ramipril—type 2 diabetes mellitus	5.48e-05	0.000297	CcSEcCtD
Sirolimus—Dyspnoea—Losartan—type 2 diabetes mellitus	5.46e-05	0.000296	CcSEcCtD
Sirolimus—Anxiety—Ramipril—type 2 diabetes mellitus	5.46e-05	0.000296	CcSEcCtD
Sirolimus—Nausea—Glyburide—type 2 diabetes mellitus	5.45e-05	0.000295	CcSEcCtD
Sirolimus—Abdominal pain—Metformin—type 2 diabetes mellitus	5.45e-05	0.000295	CcSEcCtD
Sirolimus—Dizziness—Gliclazide—type 2 diabetes mellitus	5.45e-05	0.000295	CcSEcCtD
Sirolimus—Somnolence—Losartan—type 2 diabetes mellitus	5.44e-05	0.000295	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	5.44e-05	0.000294	CcSEcCtD
Sirolimus—Asthenia—Valsartan—type 2 diabetes mellitus	5.43e-05	0.000294	CcSEcCtD
Sirolimus—Discomfort—Ramipril—type 2 diabetes mellitus	5.41e-05	0.000293	CcSEcCtD
Sirolimus—Dyspepsia—Losartan—type 2 diabetes mellitus	5.39e-05	0.000292	CcSEcCtD
Sirolimus—Asthenia—Orlistat—type 2 diabetes mellitus	5.37e-05	0.000291	CcSEcCtD
Sirolimus—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	5.36e-05	0.00029	CcSEcCtD
Sirolimus—Pruritus—Valsartan—type 2 diabetes mellitus	5.35e-05	0.00029	CcSEcCtD
Sirolimus—Decreased appetite—Losartan—type 2 diabetes mellitus	5.32e-05	0.000288	CcSEcCtD
Sirolimus—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	5.32e-05	0.000288	CcSEcCtD
Sirolimus—Confusional state—Ramipril—type 2 diabetes mellitus	5.29e-05	0.000287	CcSEcCtD
Sirolimus—Pruritus—Orlistat—type 2 diabetes mellitus	5.29e-05	0.000287	CcSEcCtD
Sirolimus—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	5.25e-05	0.000284	CcSEcCtD
Sirolimus—Oedema—Ramipril—type 2 diabetes mellitus	5.25e-05	0.000284	CcSEcCtD
Sirolimus—Vomiting—Gliclazide—type 2 diabetes mellitus	5.24e-05	0.000284	CcSEcCtD
Sirolimus—Constipation—Losartan—type 2 diabetes mellitus	5.23e-05	0.000284	CcSEcCtD
Sirolimus—Pain—Losartan—type 2 diabetes mellitus	5.23e-05	0.000284	CcSEcCtD
Sirolimus—Rash—Gliclazide—type 2 diabetes mellitus	5.19e-05	0.000281	CcSEcCtD
Sirolimus—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.19e-05	0.000281	CcSEcCtD
Sirolimus—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.18e-05	0.00028	CcSEcCtD
Sirolimus—Shock—Ramipril—type 2 diabetes mellitus	5.16e-05	0.00028	CcSEcCtD
Sirolimus—Headache—Gliclazide—type 2 diabetes mellitus	5.16e-05	0.00028	CcSEcCtD
Sirolimus—Nervous system disorder—Ramipril—type 2 diabetes mellitus	5.15e-05	0.000279	CcSEcCtD
Sirolimus—Body temperature increased—Irbesartan—type 2 diabetes mellitus	5.14e-05	0.000278	CcSEcCtD
Sirolimus—Abdominal pain—Irbesartan—type 2 diabetes mellitus	5.14e-05	0.000278	CcSEcCtD
Sirolimus—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	5.14e-05	0.000278	CcSEcCtD
Sirolimus—Tachycardia—Ramipril—type 2 diabetes mellitus	5.12e-05	0.000277	CcSEcCtD
Sirolimus—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.12e-05	0.000277	CcSEcCtD
Sirolimus—Skin disorder—Ramipril—type 2 diabetes mellitus	5.1e-05	0.000276	CcSEcCtD
Sirolimus—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	5.07e-05	0.000275	CcSEcCtD
Sirolimus—Feeling abnormal—Losartan—type 2 diabetes mellitus	5.04e-05	0.000273	CcSEcCtD
Sirolimus—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	5.01e-05	0.000271	CcSEcCtD
Sirolimus—Dizziness—Valsartan—type 2 diabetes mellitus	5.01e-05	0.000271	CcSEcCtD
Sirolimus—Anorexia—Ramipril—type 2 diabetes mellitus	5e-05	0.000271	CcSEcCtD
Sirolimus—Dizziness—Orlistat—type 2 diabetes mellitus	4.95e-05	0.000268	CcSEcCtD
Sirolimus—Asthenia—Metformin—type 2 diabetes mellitus	4.95e-05	0.000268	CcSEcCtD
Sirolimus—Hypotension—Ramipril—type 2 diabetes mellitus	4.9e-05	0.000266	CcSEcCtD
Sirolimus—Nausea—Gliclazide—type 2 diabetes mellitus	4.89e-05	0.000265	CcSEcCtD
Sirolimus—Pruritus—Metformin—type 2 diabetes mellitus	4.88e-05	0.000264	CcSEcCtD
Sirolimus—Abdominal pain—Losartan—type 2 diabetes mellitus	4.84e-05	0.000262	CcSEcCtD
Sirolimus—Body temperature increased—Losartan—type 2 diabetes mellitus	4.84e-05	0.000262	CcSEcCtD
Sirolimus—Vomiting—Valsartan—type 2 diabetes mellitus	4.81e-05	0.000261	CcSEcCtD
Sirolimus—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	4.79e-05	0.00026	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.78e-05	0.000259	CcSEcCtD
Sirolimus—Rash—Valsartan—type 2 diabetes mellitus	4.77e-05	0.000258	CcSEcCtD
Sirolimus—Dermatitis—Valsartan—type 2 diabetes mellitus	4.77e-05	0.000258	CcSEcCtD
Sirolimus—Vomiting—Orlistat—type 2 diabetes mellitus	4.76e-05	0.000258	CcSEcCtD
Sirolimus—Insomnia—Ramipril—type 2 diabetes mellitus	4.75e-05	0.000257	CcSEcCtD
Sirolimus—Headache—Valsartan—type 2 diabetes mellitus	4.74e-05	0.000257	CcSEcCtD
Sirolimus—Diarrhoea—Metformin—type 2 diabetes mellitus	4.72e-05	0.000255	CcSEcCtD
Sirolimus—Rash—Orlistat—type 2 diabetes mellitus	4.72e-05	0.000255	CcSEcCtD
Sirolimus—Paraesthesia—Ramipril—type 2 diabetes mellitus	4.71e-05	0.000255	CcSEcCtD
Sirolimus—Dermatitis—Orlistat—type 2 diabetes mellitus	4.71e-05	0.000255	CcSEcCtD
Sirolimus—Headache—Orlistat—type 2 diabetes mellitus	4.69e-05	0.000254	CcSEcCtD
Sirolimus—Dyspnoea—Ramipril—type 2 diabetes mellitus	4.68e-05	0.000253	CcSEcCtD
Sirolimus—Asthenia—Irbesartan—type 2 diabetes mellitus	4.67e-05	0.000253	CcSEcCtD
Sirolimus—Somnolence—Ramipril—type 2 diabetes mellitus	4.67e-05	0.000253	CcSEcCtD
Sirolimus—Dyspepsia—Ramipril—type 2 diabetes mellitus	4.62e-05	0.00025	CcSEcCtD
Sirolimus—Pruritus—Irbesartan—type 2 diabetes mellitus	4.6e-05	0.000249	CcSEcCtD
Sirolimus—Decreased appetite—Ramipril—type 2 diabetes mellitus	4.56e-05	0.000247	CcSEcCtD
Sirolimus—Dizziness—Metformin—type 2 diabetes mellitus	4.56e-05	0.000247	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.53e-05	0.000245	CcSEcCtD
Sirolimus—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.51e-05	0.000244	CcSEcCtD
Sirolimus—Nausea—Valsartan—type 2 diabetes mellitus	4.5e-05	0.000243	CcSEcCtD
Sirolimus—Constipation—Ramipril—type 2 diabetes mellitus	4.49e-05	0.000243	CcSEcCtD
Sirolimus—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.45e-05	0.000241	CcSEcCtD
Sirolimus—Nausea—Orlistat—type 2 diabetes mellitus	4.44e-05	0.000241	CcSEcCtD
Sirolimus—Asthenia—Losartan—type 2 diabetes mellitus	4.39e-05	0.000238	CcSEcCtD
Sirolimus—Vomiting—Metformin—type 2 diabetes mellitus	4.38e-05	0.000237	CcSEcCtD
Sirolimus—Rash—Metformin—type 2 diabetes mellitus	4.35e-05	0.000235	CcSEcCtD
Sirolimus—Dermatitis—Metformin—type 2 diabetes mellitus	4.34e-05	0.000235	CcSEcCtD
Sirolimus—Pruritus—Losartan—type 2 diabetes mellitus	4.33e-05	0.000235	CcSEcCtD
Sirolimus—Feeling abnormal—Ramipril—type 2 diabetes mellitus	4.33e-05	0.000234	CcSEcCtD
Sirolimus—Headache—Metformin—type 2 diabetes mellitus	4.32e-05	0.000234	CcSEcCtD
Sirolimus—Dizziness—Irbesartan—type 2 diabetes mellitus	4.3e-05	0.000233	CcSEcCtD
Sirolimus—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	4.29e-05	0.000232	CcSEcCtD
Sirolimus—Diarrhoea—Losartan—type 2 diabetes mellitus	4.19e-05	0.000227	CcSEcCtD
Sirolimus—Abdominal pain—Ramipril—type 2 diabetes mellitus	4.15e-05	0.000225	CcSEcCtD
Sirolimus—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.15e-05	0.000225	CcSEcCtD
Sirolimus—Vomiting—Irbesartan—type 2 diabetes mellitus	4.14e-05	0.000224	CcSEcCtD
Sirolimus—Rash—Irbesartan—type 2 diabetes mellitus	4.1e-05	0.000222	CcSEcCtD
Sirolimus—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.1e-05	0.000222	CcSEcCtD
Sirolimus—Nausea—Metformin—type 2 diabetes mellitus	4.09e-05	0.000222	CcSEcCtD
Sirolimus—Headache—Irbesartan—type 2 diabetes mellitus	4.07e-05	0.000221	CcSEcCtD
Sirolimus—Dizziness—Losartan—type 2 diabetes mellitus	4.05e-05	0.000219	CcSEcCtD
Sirolimus—Vomiting—Losartan—type 2 diabetes mellitus	3.89e-05	0.000211	CcSEcCtD
Sirolimus—Hypersensitivity—Ramipril—type 2 diabetes mellitus	3.87e-05	0.000209	CcSEcCtD
Sirolimus—Nausea—Irbesartan—type 2 diabetes mellitus	3.86e-05	0.000209	CcSEcCtD
Sirolimus—Rash—Losartan—type 2 diabetes mellitus	3.86e-05	0.000209	CcSEcCtD
Sirolimus—Dermatitis—Losartan—type 2 diabetes mellitus	3.86e-05	0.000209	CcSEcCtD
Sirolimus—Headache—Losartan—type 2 diabetes mellitus	3.83e-05	0.000208	CcSEcCtD
Sirolimus—Asthenia—Ramipril—type 2 diabetes mellitus	3.77e-05	0.000204	CcSEcCtD
Sirolimus—Pruritus—Ramipril—type 2 diabetes mellitus	3.71e-05	0.000201	CcSEcCtD
Sirolimus—Nausea—Losartan—type 2 diabetes mellitus	3.64e-05	0.000197	CcSEcCtD
Sirolimus—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.59e-05	0.000195	CcSEcCtD
Sirolimus—Dizziness—Ramipril—type 2 diabetes mellitus	3.47e-05	0.000188	CcSEcCtD
Sirolimus—Vomiting—Ramipril—type 2 diabetes mellitus	3.34e-05	0.000181	CcSEcCtD
Sirolimus—Rash—Ramipril—type 2 diabetes mellitus	3.31e-05	0.000179	CcSEcCtD
Sirolimus—Dermatitis—Ramipril—type 2 diabetes mellitus	3.31e-05	0.000179	CcSEcCtD
Sirolimus—Headache—Ramipril—type 2 diabetes mellitus	3.29e-05	0.000178	CcSEcCtD
Sirolimus—Nausea—Ramipril—type 2 diabetes mellitus	3.12e-05	0.000169	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.74e-06	3.71e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GPX1—type 2 diabetes mellitus	4.74e-06	3.71e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP2E1—type 2 diabetes mellitus	4.72e-06	3.69e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—RELA—type 2 diabetes mellitus	4.71e-06	3.68e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	4.69e-06	3.67e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARA—type 2 diabetes mellitus	4.68e-06	3.66e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP1A2—type 2 diabetes mellitus	4.67e-06	3.65e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC2A1—type 2 diabetes mellitus	4.67e-06	3.65e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	4.66e-06	3.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—C3—type 2 diabetes mellitus	4.64e-06	3.63e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CD36—type 2 diabetes mellitus	4.62e-06	3.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3R1—type 2 diabetes mellitus	4.62e-06	3.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOS3—type 2 diabetes mellitus	4.62e-06	3.61e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.61e-06	3.61e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—SRC—type 2 diabetes mellitus	4.6e-06	3.6e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.56e-06	3.57e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.56e-06	3.57e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPP2CA—type 2 diabetes mellitus	4.56e-06	3.57e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP3A4—type 2 diabetes mellitus	4.55e-06	3.56e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC2A2—type 2 diabetes mellitus	4.55e-06	3.56e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AGT—type 2 diabetes mellitus	4.53e-06	3.54e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GCG—type 2 diabetes mellitus	4.48e-06	3.5e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC2A4—type 2 diabetes mellitus	4.48e-06	3.5e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MTR—type 2 diabetes mellitus	4.46e-06	3.49e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CPT1A—type 2 diabetes mellitus	4.46e-06	3.49e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CALM1—type 2 diabetes mellitus	4.46e-06	3.48e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	4.45e-06	3.48e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	4.45e-06	3.48e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	4.45e-06	3.48e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—APOE—type 2 diabetes mellitus	4.44e-06	3.47e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.42e-06	3.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.41e-06	3.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AGT—type 2 diabetes mellitus	4.41e-06	3.44e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—APOA1—type 2 diabetes mellitus	4.39e-06	3.43e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MTHFR—type 2 diabetes mellitus	4.38e-06	3.42e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NAMPT—type 2 diabetes mellitus	4.37e-06	3.42e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—type 2 diabetes mellitus	4.37e-06	3.42e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.36e-06	3.41e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.36e-06	3.41e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—LIPC—type 2 diabetes mellitus	4.35e-06	3.4e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HBA1—type 2 diabetes mellitus	4.35e-06	3.4e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GCK—type 2 diabetes mellitus	4.35e-06	3.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.33e-06	3.39e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP11A1—type 2 diabetes mellitus	4.32e-06	3.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—LEP—type 2 diabetes mellitus	4.32e-06	3.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APOE—type 2 diabetes mellitus	4.32e-06	3.38e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARA—type 2 diabetes mellitus	4.29e-06	3.36e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—type 2 diabetes mellitus	4.28e-06	3.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.27e-06	3.34e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	4.26e-06	3.33e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	4.26e-06	3.33e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SRC—type 2 diabetes mellitus	4.25e-06	3.33e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC9A1—type 2 diabetes mellitus	4.24e-06	3.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—type 2 diabetes mellitus	4.22e-06	3.3e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CETP—type 2 diabetes mellitus	4.19e-06	3.28e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AGT—type 2 diabetes mellitus	4.16e-06	3.25e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.14e-06	3.24e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	4.12e-06	3.22e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—type 2 diabetes mellitus	4.12e-06	3.22e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	4.1e-06	3.21e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	4.1e-06	3.21e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RELA—type 2 diabetes mellitus	4.1e-06	3.21e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—type 2 diabetes mellitus	4.09e-06	3.2e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CALM1—type 2 diabetes mellitus	4.09e-06	3.2e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—APOE—type 2 diabetes mellitus	4.07e-06	3.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.07e-06	3.18e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—type 2 diabetes mellitus	4.03e-06	3.15e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	4.03e-06	3.15e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—APOA1—type 2 diabetes mellitus	4.03e-06	3.15e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NFKB1—type 2 diabetes mellitus	3.97e-06	3.1e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	3.96e-06	3.1e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	3.96e-06	3.1e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	3.96e-06	3.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—type 2 diabetes mellitus	3.95e-06	3.09e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—type 2 diabetes mellitus	3.91e-06	3.05e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PSMD6—type 2 diabetes mellitus	3.9e-06	3.05e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	3.9e-06	3.05e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	3.9e-06	3.05e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARG—type 2 diabetes mellitus	3.87e-06	3.02e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.86e-06	3.02e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GNB3—type 2 diabetes mellitus	3.86e-06	3.02e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.85e-06	3.01e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HMOX1—type 2 diabetes mellitus	3.84e-06	3e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	3.83e-06	2.99e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.8e-06	2.97e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—INS—type 2 diabetes mellitus	3.79e-06	2.97e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	3.79e-06	2.96e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—type 2 diabetes mellitus	3.79e-06	2.96e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CAT—type 2 diabetes mellitus	3.79e-06	2.96e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—type 2 diabetes mellitus	3.77e-06	2.95e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.73e-06	2.92e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	3.73e-06	2.91e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	3.72e-06	2.91e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	3.71e-06	2.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—SRC—type 2 diabetes mellitus	3.7e-06	2.89e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.7e-06	2.89e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—INS—type 2 diabetes mellitus	3.69e-06	2.88e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APOB—type 2 diabetes mellitus	3.68e-06	2.88e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.63e-06	2.84e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.6e-06	2.82e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTM1—type 2 diabetes mellitus	3.58e-06	2.8e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.57e-06	2.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.56e-06	2.79e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	3.56e-06	2.79e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARG—type 2 diabetes mellitus	3.55e-06	2.78e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	3.52e-06	2.76e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	3.52e-06	2.76e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—LPL—type 2 diabetes mellitus	3.51e-06	2.75e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.5e-06	2.73e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	3.49e-06	2.73e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—INS—type 2 diabetes mellitus	3.48e-06	2.72e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALB—type 2 diabetes mellitus	3.48e-06	2.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.46e-06	2.7e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ADCY5—type 2 diabetes mellitus	3.44e-06	2.69e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	3.44e-06	2.69e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GPX1—type 2 diabetes mellitus	3.43e-06	2.68e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SRC—type 2 diabetes mellitus	3.42e-06	2.67e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.39e-06	2.65e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	3.38e-06	2.64e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	3.38e-06	2.64e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	3.37e-06	2.63e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	3.37e-06	2.63e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	3.37e-06	2.63e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	3.37e-06	2.63e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—type 2 diabetes mellitus	3.36e-06	2.63e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CD36—type 2 diabetes mellitus	3.34e-06	2.61e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3R1—type 2 diabetes mellitus	3.33e-06	2.6e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—NOS3—type 2 diabetes mellitus	3.33e-06	2.6e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPP2CA—type 2 diabetes mellitus	3.3e-06	2.58e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—type 2 diabetes mellitus	3.24e-06	2.54e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.23e-06	2.53e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.23e-06	2.53e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	3.23e-06	2.53e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SRC—type 2 diabetes mellitus	3.22e-06	2.52e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALB—type 2 diabetes mellitus	3.19e-06	2.5e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MTHFR—type 2 diabetes mellitus	3.16e-06	2.47e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.14e-06	2.45e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARA—type 2 diabetes mellitus	3.1e-06	2.43e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—type 2 diabetes mellitus	3.1e-06	2.42e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—type 2 diabetes mellitus	3.1e-06	2.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—type 2 diabetes mellitus	3.05e-06	2.39e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3R1—type 2 diabetes mellitus	3.05e-06	2.39e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NOS3—type 2 diabetes mellitus	3.05e-06	2.39e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RELA—type 2 diabetes mellitus	3.04e-06	2.38e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—type 2 diabetes mellitus	3.04e-06	2.38e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AGT—type 2 diabetes mellitus	3.01e-06	2.35e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	3e-06	2.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—type 2 diabetes mellitus	2.99e-06	2.34e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CALM1—type 2 diabetes mellitus	2.96e-06	2.31e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APOE—type 2 diabetes mellitus	2.95e-06	2.3e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	2.91e-06	2.28e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.91e-06	2.28e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APOA1—type 2 diabetes mellitus	2.91e-06	2.28e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	2.9e-06	2.27e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.88e-06	2.25e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.87e-06	2.24e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—type 2 diabetes mellitus	2.86e-06	2.24e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	2.86e-06	2.24e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.83e-06	2.21e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	2.8e-06	2.19e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—type 2 diabetes mellitus	2.79e-06	2.18e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	2.78e-06	2.17e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	2.75e-06	2.15e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	2.75e-06	2.15e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.75e-06	2.15e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	2.7e-06	2.11e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	2.69e-06	2.11e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	2.68e-06	2.09e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	2.68e-06	2.09e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	2.68e-06	2.09e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	2.66e-06	2.08e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	2.65e-06	2.07e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.64e-06	2.07e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.61e-06	2.04e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	2.6e-06	2.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.59e-06	2.03e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	2.59e-06	2.02e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.58e-06	2.02e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.57e-06	2.01e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	2.57e-06	2.01e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	2.52e-06	1.97e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	2.52e-06	1.97e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—type 2 diabetes mellitus	2.49e-06	1.95e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	2.49e-06	1.95e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	2.4e-06	1.88e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	2.4e-06	1.88e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	2.4e-06	1.88e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SRC—type 2 diabetes mellitus	2.39e-06	1.87e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	2.39e-06	1.87e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	2.36e-06	1.84e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	2.34e-06	1.83e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	2.34e-06	1.83e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.33e-06	1.82e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	2.31e-06	1.8e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—type 2 diabetes mellitus	2.3e-06	1.8e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—type 2 diabetes mellitus	2.3e-06	1.8e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	2.29e-06	1.79e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	2.27e-06	1.77e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	2.23e-06	1.74e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	2.22e-06	1.74e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	2.21e-06	1.73e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	2.21e-06	1.73e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	2.2e-06	1.72e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	2.2e-06	1.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—type 2 diabetes mellitus	2.17e-06	1.7e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	2.17e-06	1.7e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	2.17e-06	1.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.14e-06	1.67e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—type 2 diabetes mellitus	2.12e-06	1.66e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.1e-06	1.64e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	2.08e-06	1.63e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	2.08e-06	1.63e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	2.02e-06	1.58e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—type 2 diabetes mellitus	2e-06	1.57e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.94e-06	1.51e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.9e-06	1.48e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.79e-06	1.4e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.79e-06	1.4e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.79e-06	1.4e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.76e-06	1.38e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.74e-06	1.36e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.71e-06	1.34e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.67e-06	1.3e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.67e-06	1.3e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.66e-06	1.3e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.63e-06	1.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—type 2 diabetes mellitus	1.61e-06	1.26e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.6e-06	1.25e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.59e-06	1.25e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.55e-06	1.21e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.53e-06	1.2e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—type 2 diabetes mellitus	1.53e-06	1.2e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.52e-06	1.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.49e-06	1.16e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.47e-06	1.15e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.44e-06	1.13e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—type 2 diabetes mellitus	1.4e-06	1.1e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.4e-06	1.09e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.37e-06	1.07e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.37e-06	1.07e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.35e-06	1.06e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	1.19e-06	9.33e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	1.17e-06	9.15e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	1.07e-06	8.39e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	1.03e-06	8.02e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	1.03e-06	8.02e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	1.01e-06	7.93e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	9.38e-07	7.34e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	7.65e-07	5.98e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	4.72e-07	3.69e-06	CbGpPWpGaD
